NAMS
HEALTHCARENewAmsterdam Pharma Company NV
$30.99+1.14 (+3.82%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NAMS Today?
No stock-specific AI insight has been generated for NAMS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.79$42.00
$30.99
Fundamentals
Market Cap$3.6B
P/E Ratio—
EPS$-1.72
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding115.0M
NAMS News
20 articles- Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?Yahoo Finance·May 8, 2026
- NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded TrendsMarketbeat·May 8, 2026
- NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsYahoo Finance·May 7, 2026
- A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C ResultsYahoo Finance·Apr 9, 2026
- NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan DruckenmillerYahoo Finance·Apr 8, 2026
- NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 2, 2026
- Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4Yahoo Finance·Apr 2, 2026
- Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS)Yahoo Finance·Mar 29, 2026
- NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific SessionYahoo Finance·Mar 23, 2026
- This Biotech Was Quietly Bought Before a $58 Per Share TakeoutMotley Fool·Mar 21, 2026
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MarchYahoo Finance·Feb 25, 2026
- The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share OfferingYahoo Finance·Feb 23, 2026
- NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 18, 2026
- NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech SummitMarketbeat·Feb 14, 2026
- NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech SummitYahoo Finance·Feb 4, 2026
- Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price VolatilityYahoo Finance·Jan 14, 2026
- Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsightYahoo Finance·Jan 12, 2026
- NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic PrioritiesYahoo Finance·Jan 9, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$29.85
Day High$0.00
Day Low$0.00
52 Week High$42.00
52 Week Low$16.79
52-Week Range
$16.79$42.00
$30.99
Fundamentals
Market Cap$3.6B
P/E Ratio—
EPS$-1.72
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding115.0M
About NewAmsterdam Pharma Company NV
NewAmsterdam Pharma Company N.V. is a pioneering biotechnology firm dedicated to developing innovative therapies for cardiometabolic diseases. Leveraging its proprietary technology platform, the company targets significant unmet medical needs and boasts a strong clinical development pipeline. With a seasoned leadership team and a commitment to advancing treatment paradigms, NewAmsterdam is well-positioned for growth and offers investors a compelling opportunity to engage in transformative therapeutic initiatives that aim to improve patient outcomes.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—